Study shows potential of stem cell therapy to repair lung damage

March 24, 2017

A new study has found that stem cell therapy can reduce lung inflammation in an animal model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Although, still at a pre-clinical stage, these findings have important potential implications for the future treatment of patients.

The findings were presented in Estoril, Portugal today (25 March, 2017) at the European Respiratory Society's Lung Science Conference.

Lung damage caused by chronic inflammation in conditions such as COPD and , leads to reduced and eventually respiratory failure. Mesenchymal stem cell (MSC) is currently being investigated as a promising therapeutic approach for a number of incurable, degenerative lung diseases. However, there is still limited data on the short and long-term effects of administering in chronic respiratory .

The new research investigated the effectiveness of MSC therapy in a mouse model of chronic inflammatory lung disease, which reflects some of the essential features of diseases such as COPD and cystic fibrosis.

Researchers delivered stem cells intravenously to β-ENaC overexpressing mice at 4 and 6 weeks of age, before collecting samples tissue and cells from the lungs at 8 weeks. They compared these findings to a control group that did not receive the MSC therapy.

The results showed that inflammation was significantly reduced in the group receiving MSC therapy. Cells counts for both monocytic cells and neutrophils, both signs of inflammation, were significantly reduced after MSC therapy. Analysis of lung tissue revealed a reduction in the mean linear intercept and other measures of lung destruction in MSC treated mice. As well as reducing inflammation in the lung, MSC therapy also resulted in significant improvements in lung structure, suggesting that this form of treatment has the potential to repair the damaged lung.

Dr Declan Doherty, from Queens University Belfast, UK, commented: "These preliminary findings demonstrate the potential effectiveness of MSC treatment as a means of repairing the damage caused by such as COPD. The ability to counteract inflammation in the lungs by utilising the combined anti-inflammatory and reparative properties of MSCs could potentially reduce the inflammatory response in individuals with chronic lung disease whilst also restoring lung function in these patients. Although further research is needed to improve our understanding of how MSCs repair this damage, these findings suggest a promising role for MSC therapy in treating patients with chronic lung disease.

Professor Rachel Chambers, ERS Conferences and Research Seminars Director, commented: This paper offers novel results in a pre-clinical model which demonstrates the potential of MSC stem cell therapy for the treatment of long-term lung conditions with exciting potential implications for the future treatment of patients with COPD and cystic fibrosis. Although, still at an early stage in terms of translation to the human disease situation, this paper is one of many cutting-edge abstracts from the Lung Science Conference, which aims to provide an international platform to highlight novel experimental research with therapeutic potential. We rely on high quality basic and translational respiratory science, such as these latest findings, to develop novel therapeutic approaches for the millions of patients suffering from devastating and often fatal respiratory conditions.

Explore further: DNA-modulating drug attenuates lung inflammation in mice

Related Stories

DNA-modulating drug attenuates lung inflammation in mice

July 21, 2016
Patients with cystic fibrosis (CF) suffer from chronic respiratory infections, primarily caused by Pseudomonas aeruginosa, which lead to airway inflammation and damage. Several recent studies have suggested that a specific ...

Gene delivery to the lung can treat broad range of diseases within and beyond the lung

January 25, 2017
Targeting therapeutic genes to the lungs offers the potential to manage serious lung diseases that do not respond to other forms of treatment and to use the lungs as metabolic factories to produce therapeutic proteins for ...

Team discovers lung regeneration mechanism

November 12, 2014
A research team led by Jackson Laboratory Professors Frank McKeon, Ph.D., and Wa Xian, Ph.D., reports on the role of certain lung stem cells in regenerating lungs damaged by disease.

Study finds shared network of genes in COPD and pulmonary fibrosis

April 25, 2016
Research on chronic lung diseases has primarily focused on studying conditions, such as emphysema or lung fibrosis, in isolation. In a new study, Yale scientists identified a common genetic network for two chronic lung diseases ...

Recommended for you

New approach to tracking how deadly 'superbugs' travel could slow their spread

November 22, 2017
Killer bacteria - ones that have out-evolved our best antibiotics—may not go away anytime soon. But a new approach to tracking their spread could eventually give us a fighting chance to keep their death toll down.

Research points to diagnostic test for top cause of liver transplant in kids

November 22, 2017
Biliary atresia is the most common cause of liver transplants for children in the United States. Now researchers report in Science Translational Medicine finding a strong biomarker candidate that could be used for earlier ...

Metabolites altered in chronic kidney disease

November 22, 2017
Chronic kidney disease (CKD) affects 1 in 7 people in the United States, according to the U.S. National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK). These individuals have a very high risk of cardiovascular ...

Rainfall can indicate that mosquito-borne epidemics will occur weeks later

November 22, 2017
A new study demonstrates that outbreaks of mosquito-borne viruses Zika and Chikungunya generally occur about three weeks after heavy rainfall.Researchers also found that Chikungunya will predominate over Zika when both circulate ...

Alcohol consumption and metabolic factors act together to increase the risk of severe liver disease

November 22, 2017
A new study provides insights into the interaction between alcohol consumption and metabolic factors in predicting severe liver disease in the general population. The findings, which are published in Hepatology, indicate ...

Gastric acid suppressant lansoprazole may target tuberculosis

November 21, 2017
A cheap and widely used drug, used to treat conditions such as heartburn, gastritis and ulcers, could work against the bacteria that cause tuberculosis (TB), according to new research from UCL and the London School of Hygiene ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.